Role gadolinium plays in NSF incidence remains unclear

June 3, 2008 Diagnostic Imaging. Role gadolinium plays in NSF incidence remains unclear Evidence of effects of macrocyclic versus linear chelates and free versus bound elements lacks strength to provide proof of connection -------------------------------------------------------------------------------- The controversial topic of nephrogenic systemic fibrosis featured prominently in this year's European Congress of Radiology program. This scleroderma-like disorder has been linked to the administration of gadolinium-containing contrast media. Despite the growing wealth of data on incidence of the disorder, however, researchers remain unable to pin down the causal trigger. All cases of NSF reported since its first identification in 1997 have involved patients with advanced renal disease. Most of these patients had previously undergone imaging with a gadolinium-based agent on one or more occasions.

See full article and related articles at DiagnosticImaging.com
This article was republished with permission from CMPMedica, LLC